Publications by authors named "Rui Kitadai"

Claim this Profile
T
Treatment and Reasons for Choosing Treatment in Breast Cancer Patients Who Underwent Next-Generation Sequencing Test.
Kazuki Sudo, Rumi Nishimura, Kazuki Sudo, Rui Kitadai, Asuka Kawachi

Oncology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline risk variability by eligibility criteria in Cohort 1 of the monarchE trial for high-risk HR-positive, HER2-negative breast cancer.
Mai Hoshino, Tatsunori Shimoi, Taro Yamanaka, Rui Kitadai, Munehiro Ito

Breast Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer.
Shu Yazaki, Rui Kitadai, Yukihide Momozawa, Teruhiko Yoshida, Takashi Yamanaka

NPJ Breast Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository" [Eur J Cancer 220 (2025) 115380].
Rui Kitadai, Yusuke Okuma, Taro Shibata, Takashi Kohno, Takafumi Koyama

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository.
Rui Kitadai, Yusuke Okuma, Taro Shibata, Takashi Kohno, Takafumi Koyama

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer.
Rui Kitadai, Shu Yazaki, Aya Kuchiba, Takashi Yamanaka, Sho Shiino

Cancer Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer.
Shu Yazaki, Yohei Chiba, Yuki Kojima, Hiroshi Yoshida, Shigemasa Takamizawa, Rui Kitadai

Int J Gynecol Pathol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.
Rui Kitadai, Tatsunori Shimoi, Shu Yazaki, Hitomi Sumiyoshi Okuma, Mai Hoshino

Breast Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study.
Momoko Tokura, Mark Malalay Ando, Yuki Kojima, Rui Kitadai, Shu Yazaki

Breast Cancer (Auckl)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trop-2 expression and the tumor immune microenvironment in cervical cancer.
Yohei Chiba, Yuki Kojima, Shu Yazaki, Hiroshi Yoshida, Shigemasa Takamizawa, Rui Kitadai

Gynecol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).
Tetsuhiko Asao, Takehito Shukuya, Kohei Uemura, Rui Kitadai, Gaku Yamamoto

Lung Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.
Rui Kitadai, Tadaaki Nishikawa, Hiroshi Yoshida, Chiharu Mizoguchi, Kasumi Yamamoto

J Gynecol Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Ayumi Saito, Tadaaki Nishikawa, Hiroshi Yoshida, Chiharu Mizoguchi, Rui Kitadai

Gynecol Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discordances in expression of human epidermal growth factor receptor 2 between primary and metastatic uterine carcinosarcoma: A proposal for HER2-targeted therapy specimen selection.
Hiroshi Yoshida, Chiharu Mizoguchi, Ayumi Saito, Rui Kitadai, Kasumi Yamamoto

Ann Diagn Pathol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of drugs targeting hypoxia-inducible factor against tumor cells with VHL mutation: Story of 127 years.
Hajime Takamori, Toshinari Yamasaki, Rui Kitadai, Yoji Andrew Minamishima, Eijiro Nakamura

Cancer Sci· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer.
Tomomi Sanomachi, Hitomi Sumiyoshi Okuma, Rui Kitadai, Asuka Kawachi, Shu Yazaki

Front Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer.
Shu Yazaki, Yuki Kojima, Hiroshi Yoshida, Shigemasa Takamizawa, Rui Kitadai

J Gynecol Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study.
Shigemasa Takamizawa, Shu Yazaki, Yuki Kojima, Hiroshi Yoshida, Rui Kitadai

BMC Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis.
Rui Kitadai, Yusuke Okuma

Cancers (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracranial complete response for non-small-cell lung cancer patient with negative PD-L1 expression of the lung using nivolumab.
Rui Kitadai, Yoshitaka Zenke, Tsunekazu Hishima, Yukio Hosomi

Cancer Rep (Hoboken)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy.
Yuji Uehara, Taiki Hakozaki, Rui Kitadai, Kosuke Narita, Kageaki Watanabe

Transl Lung Cancer Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma.
Rui Kitadai, Yusuke Okuma

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
Rui Kitadai, Tatsunori Shimoi, Kazuki Sudo, Emi Noguchi, Yusuke Nagata

BMC Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
Antoine Desilets, Félix Blanc-Durand, Sally Lau, Taiki Hakozaki, Rui Kitadai

Eur J Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
Taiki Hakozaki, Yukio Hosomi, Akihiro Shimizu, Rui Kitadai, Kie Mirokuji

J Cancer Res Clin Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis